Please assess the completion status of the following clinical trial:

Trial Title: Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age 18-75 years old)~* Outpatient~* Third or further documented CDI episode and~* Unable to maintain CDI cure after standard therapy with oral vancomycin or fidaxomicin~  * Previous treatment with at least one course of tapered/pulse vancomycin or~ * Inability to taper or stop vancomycin or fidaxomicin without developing diarrhea requiring antibiotic therapy.~* Improvement of CDI symptoms on vancomycin or fidaxomicin~Exclusion Criteria:~* Unable to comply with study follow-up procedures at discretion of MD~* Unable to provide informed consent at discretion of MD~* Participating in another clinical trial~* Pregnant or nursing currently or planned pregnancy in next 1 year~* Evidence of toxic megacolon or gastrointestinal perforation~* Peripheral white blood cell count \>30 x 10\^9/L and/or temperature \>38 degrees Celsius~* Admission to an intensive care unit within prior 7 days for any reason~* Previously undergone FMT~* Severely immunocompromised patients~  * HIV infection (any CD4 count)~ * AIDS-defining diagnoses~ * Inherited/primary immune disorder~ * Immunosuppressant medications:~* Current or recent (\<3 months) treatment with anti-neoplastic agents~* Current or recent (\<3 months) treatment with calcineurin inhibitors (tacrolimus, cyclosporine)~* Current or recent (\<3 months) treatment with mycophenolate mofetil~* Current or recent (\<3 months) treatment with monoclonal antibodies to B and T-Cells, anti-TNF, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine)~* Neutropenia with absolute neutrophil count (ANC) \<0.5 x 10\^9/L~* Active gastroenteritis due to infectious cause other than CDI~* Short gut syndrome~* Colostomy~* Ascites~* End-stage liver disease~* Untreated, in-situ colorectal cancer~* Irritable bowel syndrome~* Inflammatory bowel disease including Crohn's disease and ulcerative colitis~* Microscopic colitis including collagenous colitis and lymphocytic colitis~* Severe food allergy (anaphylaxis) that cannot be confirmed as having been excluded from a donor's diet within the five days prior to donation~* Anorectal disorder/severe rectal sphincter tone abnormality or inability to retain enema material~* Unable or unwilling to tolerate colonoscopy/sigmoidoscopy, colonoscopy prep, or enema for any reason at discretion of MD~* Severe underlying disease that the patient is not expected to survive for the subsequent 12 months at the discretion of the MD.~* Any conditions for which, in opinion of MD, the treatment may pose a health risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention: Fecal Microbiota Preparation (Type: EXPERIMENTAL): Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor

Based on this trial design, predict the completion outcome and termination type (if applicable).